Arthneeti
Latest: Dhanuka Agritech Ltd Q2 FY27 results →All Q3 FY26 results →
DA

Dhanuka Agritech Ltd

Q3 FY26Fertilizers & Agrochemicals

Dhanuka Agritech Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management said on revenue, margins and capex.

Price₹980
Market cap₹4.5K Cr
P/E16.7
Updated23 Aug 2026
Read3 min read

The short version

Dhanuka Agritech expects healthy double-digit growth over the next 3 to 5 years. Dhanuka Agritech expects healthy double-digit growth over the next 3 to 5 years, driven by favorable macroeconomic factors and increased value-added crop cultivation.

From Dhanuka Agritech Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Dhanuka Agritech expects healthy double-digit growth over the next 3 to 5 years.
  • Growth drivers include expansion in existing products, new molecules, exports, and entry into new crops.
  • Favorable macroeconomic factors boost agriculture and agri-input industries.
  • Increasing multiple crop cycles per year due to better irrigation and marketability of produce.
  • Agrochemical consumption in India is low (~600 grams/hectare) compared to world averages, indicating significant growth potential.
  • The company focuses on specialized, value-added crops (grapes, tomato, chilli) as well as conventional crops (rice, soybean, cotton, tea).
  • Growth depends on better reach to every cultivating field and intensifying market penetration.
  • Q4 shows promise of growth, but full year may be flattish for short term.

2 more points from Dhanuka Agritech Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Dhanuka Agritech Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • For FY'27, Dhanuka Agritech is commissioning an MPP-2 plant with an expected CAPEX of Rs. 60-70 crores.
  • The MPP-2 plant will produce three products, including Bifenthrin, Difenoconazole, and a new product Iprovalicarb, targeting 80% capacity utilization next year.
  • Discussions are ongoing with multinational players, including one Japanese and one European company, for potential exclusive contract manufacturing or strategic partnerships at the Dahej manufacturing facility.

Top-ranked in Fertilizers & Agrochemicals

Ranked on what management guided this quarter

Guidance-ranked
1Anya Polytech &
Rev 2Mar 1
2Dharmaj Crop
Rev 2Mar 2
3
Rev 2Mar 3
4
Rev 2Mar 3
5
Rev 3Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Dhanuka Agritech Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Relevant points regarding business outlook and sales visibility include: - FY'27 planning has been initiated, with expectations of a normal year ahead. - Q4 has started well with good demand in South and East Indian paddy and wheat crops. - The team is working on export sales for Bayer molecules, with better assessment expected by end of March. - Capacity utilization for the Dahej MPP-2 plant is targeted at ~80% in FY'27 for three products.

2 more points from Dhanuka Agritech Ltd's call on order book

Create a free account to keep reading this call

Dhanuka Agritech Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹483 Cr, net profit ₹98 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Dhanuka Agritech Ltd's management said in earlier quarters

Others in Fertilizers & Agrochemicals this season

  • Bhagiradha Chemicals & Industries Ltd (Q3 FY26)

    114.0 crore, up 11% YoY from Rs. Key investor presentation takeaways from Bhagiradha Chemicals & Industries Ltd's Q3 FY26 investor presentation — and how it ran

  • Advance Agrolife Ltd (Q3 FY26)

    Q3 FY26 revenue from operations was ₹1,338 million, up 18% year-on-year (YoY) from ₹1,134 million in Q3 FY25 (Pages 23-24). Key investor presentation takeaways

  • Khaitan Chemicals & Fertilizers Ltd (Q3 FY26)

    Q3-FY26 operational revenue: INR 2,657 million, up 34% year-on-year (Page 23, 24). Key investor presentation takeaways from Khaitan Chemical's Q3 FY26 investor

  • Rama Phosphates Ltd (Q3 FY26)

    Q3 FY26 Revenue from Operations: ₹23,800 lakhs, up 33% YoY (Q3 FY25: ₹17,962 lakhs) [Page 9] . Key investor presentation takeaways from Rama Phosphates's Q3 FY2

Compare:vs Coromandel Intervs UPL Ltdvs F A C T

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Dhanuka Agritech Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Dhanuka Agritech Ltd Q3 FY26 results?

Dhanuka Agritech expects healthy double-digit growth over the next 3 to 5 years. Dhanuka Agritech expects healthy double-digit growth over the next 3 to 5 years, driven by favorable macroeconomic factors and increased value-added crop cultivation.

What is Dhanuka Agritech Ltd share price analysis?

Dhanuka Agritech Ltd currently shows a neutral. The stock trades at a P/E of 16.7 with a market cap of ₹4,482 Cr. Investors should review the full earnings analysis for detailed insights.

Is Dhanuka Agritech Ltd planning capital expenditure?

For FY'27, Dhanuka Agritech is commissioning an MPP-2 plant with an expected CAPEX of Rs.

Keep Dhanuka Agritech Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.